Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Hypertension I: Introduction01:28

Hypertension I: Introduction

1.3K
Hypertension is a widespread, long-term medical condition where blood pressure in the arteries remains elevated. It is characterized by systolic blood pressure readings of 130 mm Hg or above or diastolic blood pressure (DBP) readings of 80 mm Hg or higher. Unmanaged hypertension poses significant health risks, making the distinction between primary (or essential) hypertension and secondary hypertension crucial, as their management and implications vary.Primary HypertensionPrimary hypertension,...
1.3K
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

4.8K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
4.8K
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

1.6K
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
1.6K
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

773
Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
773
Hypertension V: Nursing Management01:23

Hypertension V: Nursing Management

662
The nursing management of hypertension involves accurately assessing symptoms, making a comprehensive nursing diagnosis, collaborating with patients to set goals, and implementing targeted interventions to mitigate the condition's impact and improve patient well-being.Comprehensive AssessmentThe initial step in nursing care for hypertension involves a thorough patient assessment. It includes evaluating symptoms such as headaches, dizziness, blurred vision, and previous hypertension episodes.
662
Alterations in Blood Pressure01:30

Alterations in Blood Pressure

2.5K
Alterations in blood pressure, such as hypertension (high blood pressure) and hypotension (low blood pressure), significantly affect human health. Understanding these conditions' classifications, causes, and symptoms is essential for effective management and treatment.
Hypertension (High blood pressure)
Hypertension occurs when blood pressure readings consistently exceed the normal range. It is diagnosed when systolic blood pressure (the top number, indicating pressure while the heart...
2.5K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Development of a risk prediction model for postpartum onset of type 2 diabetes mellitus, following gestational diabetes; the lifestyle InterVention in gestational diabetes (LIVING) study.

Clinical nutrition (Edinburgh, Scotland)·2024
Same author

Effect of Yoga-Based Cardiac Rehabilitation Program on Endothelial Function, Oxidative Stress, and Inflammatory Markers in Acute Myocardial Infarction: A Randomized Controlled Trial.

International journal of yoga·2024
Same author

Author Correction: Fixed-dose combination therapy for the prevention of atherosclerotic cardiovascular disease.

Nature medicine·2024
Same author

Establishing Apolipoprotein-B and non-high-density-lipoprotein-C goals in Indian population: A Cross-sectional study.

Indian heart journal·2024
Same author

Prevalence and Correlates of Vitamin D Deficiency among Adult Population in Urban and Rural Areas of the National Capital Region of Delhi, India.

WHO South-East Asia journal of public health·2024
Same author

Potential Mediating Role of Iron Biomarkers in the Association of Sex With Glucose, Insulin, and Type 2 Diabetes.

Journal of the Endocrine Society·2024
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
関連記事をすべて見る

関連する実験動画

Updated: Apr 15, 2026

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

1.3K

高血圧の高血圧は,高血圧の高血圧を意味する.

Neil R Poulter1, Dorairaj Prabhakaran2, Mark Caulfield3

  • 1International Centre for Circulatory Health, Imperial College London, London, UK.

Lancet (London, England)
|April 3, 2015
PubMed
まとめ
この要約は機械生成です。

高血圧は,世界の主要な健康問題です. 効果的な予防と高血圧の最適化管理,そして手頃な価格の多剤療法が,特に発展途上国では極めて重要です.

さらに関連する動画

Simultaneous Electrocardiography Recording and Invasive Blood Pressure Measurement in Rats
07:35

Simultaneous Electrocardiography Recording and Invasive Blood Pressure Measurement in Rats

Published on: January 31, 2019

16.8K
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

8.2K

関連する実験動画

Last Updated: Apr 15, 2026

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug
05:57

Author Spotlight: Exploring Huotan Jiedu Tongluo Decoction as an Antihypertensive Drug

Published on: May 17, 2024

1.3K
Simultaneous Electrocardiography Recording and Invasive Blood Pressure Measurement in Rats
07:35

Simultaneous Electrocardiography Recording and Invasive Blood Pressure Measurement in Rats

Published on: January 31, 2019

16.8K
Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

8.2K

科学分野:

  • 心臓病学 心臓病学
  • 公衆衛生は公衆衛生である.
  • 遺伝学 遺伝学とは

背景:

  • 高血圧 (高血圧) は,疾病負担と死亡率の主要な世界的な要因です.
  • 世界的に高血圧の罹患率は,今後10年間で著しく上昇すると予測されています.
  • 高血圧に関する現在の遺伝的洞察は,全般的な血圧管理にほとんど影響を与えない.

研究 の 目的:

  • 世界的に予防戦略と最適化された高血圧管理の緊急の必要性を強調する.
  • 環境的決定要因に対処し,証拠に基づいた治療法を導入することの重要性を強調する.
  • 組み合わせた薬物療法と民族特有の治療評価の可能性を調査する.

主な方法:

  • 高血圧に関連する世界的な疾病負担と死亡率のデータのレビュー.
  • 高血圧の原因に関する現在の遺伝子研究の分析.
  • マルチドラッグ高血圧レジメントの有効性と資源への影響の評価.

主要な成果:

  • 高血圧は,世界の死亡率と疾患の主な原因であり続けています.
  • 環境要因と治療の実施は,血圧のコントロールに極めて重要です.
  • 3つの薬剤の組み合わせにより,高血圧制御率 (約. 90%) が,手頃な価格でアクセス可能な場合です.

結論:

  • 予防戦略の緊急実施と高血圧管理の最適化が求められているのは,特に発展途上国において顕著である.
  • 環境への介入と効果的な治療の実施は,血圧のコントロールの鍵です.
  • 高血圧の最適なコントロールには,手頃な価格でアクセス可能な組み合わせ療法と民族特有の治療戦略が不可欠です.